Animal models of Aspergillus infection in preclinical trials, diagnostics and pharmacodynamics: What can we learn from them?

References

• Clemons KV, Stevens DA. The contribution of animal models of aspergillosis to understanding pathogenesis, therapy and virulence. Med Mycol 2005; 43(Suppl. 1)S101–110
   PubMed Web of Science ®Google Scholar
• Stevens DA. Animal models in the evaluation of antifungal drugs. J Mycol Med 1996; 6(Suppl. I)7–10
   Google Scholar
• Polak A. Experimental models in antifungal chemotherapy. Mycoses 1998; 41: 1–30
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Animal models testing monotherapy versus combination antifungal therapy: lessons learned and future directions. Curr Opin Infect Dis 2006; 19: 360–364.
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Immunomodulation of fungal infections: do immunomodulators have a role in treating mycoses?. EOS Rivista Immunol Immunofarmacol 2002; 22: 29–32
   Google Scholar
• Kurup VP, Grunig G. Animal models of allergic bronchopulmonary aspergillosis. Mycopathologia 2002; 153: 165–177
   PubMed Web of Science ®Google Scholar
• Latge JP. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev 1999; 12: 310–350
   PubMed Web of Science ®Google Scholar
• Patterson TF. The future of animal models of invasive aspergillosis. Med Mycol 2005; 43(Suppl. 1)S115–119
   PubMedGoogle Scholar
• Chiller TM, Luque JC, Sobel RA, et al. Development of a murine model of cerebral aspergillosis. J Infect Dis 2002; 186: 574–577
   PubMed Web of Science ®Google Scholar
• Denning DW, Stevens DA. Efficacy of cilofungin alone and in combination with amphotericin B in a murine model of disseminated aspergillosis. Antimicrob Agents Chemother 1991; 35: 1329–1333
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against experimental pulmonary aspergillosis. Med Mycol 2006; 44: 69–73
   PubMed Web of Science ®Google Scholar
• Dufour X, Kauffmann-Lacroix C, Goujon JM, et al. Experimental model of fungal sinusitis: a pilot study in rabbits. Ann Otol Rhinol Laryngol 2005; 114: 167–172
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, McAtee RK, Fothergill AW, Rinaldi MG, Patterson TF. Efficacy of voriconazole in a guinea pig model of disseminated invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 2865–2868
   PubMed Web of Science ®Google Scholar
• Lionakis MS, Kontoyiannis DP. Fruit flies as a minihost model for studying drug activity and virulence in Aspergillus. Med Mycol 2005; 43(Suppl. 1)S111–114
   Google Scholar
• O'Day DM, Head WS, Robinson RD, Williams TE, Gedde S. The evaluation of therapeutic responses in experimental keratomycosis. Curr Eye Res 1992; 11: 35–44
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Garrett K, Feurerstein E, et al. Therapeutic monitoring of experimental invasive pulmonary aspergillosis by ultrafast computerized tomography, a novel, noninvasive method for measuring responses to antifungal therapy. Antimicrob Agents Chemother 1995; 39: 1065–1069
   PubMed Web of Science ®Google Scholar
• Schmidt A. Animal models of aspergillosis-also useful for vaccination strategies?. Mycoses 2002; 45: 38–40
   PubMed Web of Science ®Google Scholar
• Van Cutsem J, Van Gerven F, Janssen PA. Oral and parenteral therapy with saperconazole (R 66905) of invasive aspergillosis in normal and immunocompromised animals. Antimicrob Agents Chemother 1989; 33: 2063–2068
   PubMed Web of Science ®Google Scholar
• Kurup VP, Sheth NK. Experimental aspergillosis in rabbits. Comp Immunol Microbiol Infect Dis 1981; 4: 161–174
   PubMed Web of Science ®Google Scholar
• Sheppard DC, Rieg G, Chiang LY, et al. Novel inhalational murine model of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2004; 48: 1908–1911
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Jr, Trasi SA, et al. Value of an inhalational model of invasive aspergillosis. Med Mycol 2004; 42: 417–425
   PubMed Web of Science ®Google Scholar
• Bowman JC, Abruzzo GK, Anderson JW, et al. Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob Agents Chemother 2001; 45: 3474–3481
   PubMed Web of Science ®Google Scholar
• Singh G, Imai J, Clemons KV, Stevens DA. Efficacy of caspofungin against central nervous system Aspergillus fumigatus infection in mice determined by TaqMan PCR and CFU methods. Antimicrob Agents Chemother 2005; 49: 1369–1376
   PubMed Web of Science ®Google Scholar
• Balloy V, Huerre M, Latge JP, Chignard M. Differences in patterns of infection and inflammation for corticosteroid treatment and chemotherapy in experimental invasive pulmonary aspergillosis. Infect Immun 2005; 73: 494–503
   PubMed Web of Science ®Google Scholar
• MacCallum DM, Whyte JA, Odds FC. Efficacy of caspofungin and voriconazole combinations in experimental aspergillosis. Antimicrob Agents Chemother 2005; 49: 3697–3701
   PubMed Web of Science ®Google Scholar
• Francis P, Lee JW, Hoffman A, et al. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J Infect Dis 1994; 169: 356–368
   PubMed Web of Science ®Google Scholar
• Dupont B, Huber M, Kim SJ, Bennett JE. Galactomannan antigenemia and antigenuria in aspergillosis: studies in patients and experimentally infected rabbits. J Infect Dis 1987; 155: 1–11
   PubMed Web of Science ®Google Scholar
• Loeffler J, Kloepfer K, Hebart H, et al. Polymerase chain reaction detection of Aspergillus DNA in experimental models of invasive aspergillosis. J Infect Dis 2002; 185: 1203–1206
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, et al. Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004; 190: 641–649
   PubMed Web of Science ®Google Scholar
• Becker MJ, de Marie S, Willemse D, Verbrugh HA, Bakker-Woudenberg IA. Quantitative galactomannan detection is superior to PCR in diagnosing and monitoring invasive pulmonary aspergillosis in an experimental rat model. J Clin Microbiol 2000; 38: 1434–1438
   PubMed Web of Science ®Google Scholar
• Hurst SF, Reyes GH, McLaughlin DW, Reiss E, Morrison CJ. Comparison of commercial latex agglutination and sandwich enzyme immunoassays with a competitive binding inhibition enzyme immunoassay for detection of antigenemia and antigenuria in a rabbit model of invasive aspergillosis. Clin Diagn Lab Immunol 2000; 7: 477–485
   PubMedGoogle Scholar
• Segal BH, Walsh TJ. Current approaches to diagnosis and treatment of invasive aspergillosis. Am J Respir Crit Care Med 2006; 173: 707–717
   PubMed Web of Science ®Google Scholar
• Verweij PE. Advances in diagnostic testing. Med Mycol 2005; 43(Suppl. 1)S121–124
   PubMedGoogle Scholar
• Capilla Luque J, Clemons KV, Stevens DA. Efficacy of micafungin alone or in combination against systemic murine aspergillosis. Antimicrob Agents Chemother 2003; 47: 1452–1455
   PubMed Web of Science ®Google Scholar
• Clemons KV, Stevens DA. Comparative efficacies of four amphotericin B formulations –Fungizone, Amphotec (Amphocil), AmBisome, and Abelcet – against systemic murine aspergillosis. Antimicrob Agents Chemother 2004; 48: 1047–1050
   PubMed Web of Science ®Google Scholar
• Hanson LH, Clemons KV, Denning DW, Stevens DA. Efficacy of oral saperconazole in systemic murine aspergillosis. J Med Vet Mycol 1995; 33: 311–317
   PubMedGoogle Scholar
• Clemons KV, Espiritu M, Parmar R, Stevens DA. Comparative efficacies of conventional amphotericin B, liposomal amphotericin B (AmBisome), caspofungin, micafungin, and voriconazole alone and in combination against experimental murine central nervous system aspergillosis. Antimicrob Agents Chemother 2005; 49: 4867–4875
   PubMed Web of Science ®Google Scholar
• Imai J, Singh G, Fernandez B, Clemons KV, Stevens DA. Efficacy of Abelcet and caspofungin, alone or in combination, against CNS aspergillosis in a murine model. J Antimicrob Chemother 2005; 56: 166–171
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R, Gonzalez GM, Najvar LK. Combination antifungal therapy of murine aspergillosis: liposomal amphotericin B and micafungin. J Antimicrob Chemother 2003; 52: 656–662
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, McAtee RK, Fothergill AW, et al. Efficacy of SCH56592 in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 2000; 44: 780–782
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis. J Antimicrob Chemother 2002; 49: 353–357
   PubMed Web of Science ®Google Scholar
• Patterson TF, Fothergill AW, Rinaldi MG. Efficacy of itraconazole solution in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 1993; 37: 2307–2310
   PubMed Web of Science ®Google Scholar
• Patterson TF, George D, Ingersoll R, Miniter P, Andriole VT. Efficacy of SCH 39304 in treatment of experimental invasive aspergillosis. Antimicrob Agents Chemother 1991; 35: 1985–1988
   PubMed Web of Science ®Google Scholar
• Patterson TF, George D, Miniter P, Andriole VT. The role of fluconazole in the early treatment and prophylaxis of experimental invasive aspergillosis. J Infect Dis 1991; 164: 575–580
   PubMed Web of Science ®Google Scholar
• Patterson TF, George D, Miniter P, Andriole VT. Saperconazole therapy in a rabbit model of invasive aspergillosis. Antimicrob Agents Chemother 1992; 36: 2681–2685
   PubMed Web of Science ®Google Scholar
• Patterson TF, Miniter P, Andriole VT. Efficacy of fluconazole in experimental invasive aspergillosis. Rev Infect Dis 1990; 12(Suppl. 3)S281–285
   Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001; 45: 857–869
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Groll AH, et al. Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob Agents Chemother 2002; 46: 12–23
   PubMed Web of Science ®Google Scholar
• Petraitiene R, Petraitis V, Lyman CA, et al. Efficacy, safety, and plasma pharmacokinetics of escalating dosages of intravenously administered ravuconazole lysine phosphoester for treatment of experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2004; 48: 1188–1196
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Antifungal efficacy, safety, and single-dose pharmacokinetics of LY303366, a novel echinocandin B, in experimental pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 1998; 42: 2898–2905
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Groll AH, et al. Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits. Antimicrob Agents Chemother 2002; 46: 1857–1869
   PubMed Web of Science ®Google Scholar
• Berenguer J, Ali NM, Allende MC, et al. Itraconazole for experimental pulmonary aspergillosis: comparison with amphotericin B, interaction with cyclosporin A, and correlation between therapeutic response and itraconazole concentrations in plasma. Antimicrob Agents Chemother 1994; 38: 1303–1308
   PubMed Web of Science ®Google Scholar
• Ruijgrok EJ, Fens MH, Bakker-Woudenberg IA, van Etten EW, Vulto AG. Nebulization of four commercially available amphotericin B formulations in persistently granulocytopenic rats with invasive pulmonary aspergillosis: evidence for long-term biological activity. J Pharm Pharmacol 2005; 57: 1289–1295
   PubMed Web of Science ®Google Scholar
• Ruijgrok EJ, Vulto AG, Van Etten EW. Efficacy of aerosolized amphotericin B desoxycholate and liposomal amphotericin B in the treatment of invasive pulmonary aspergillosis in severely immunocompromised rats. J Antimicrob Chemother 2001; 48: 89–95
   PubMed Web of Science ®Google Scholar
• Hoeben BJ, Burgess DS, McConville JT, et al. In vivo efficacy of aerosolized nanostructured itraconazole formulations for prevention of invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2006; 50: 1552–1554
   PubMed Web of Science ®Google Scholar
• Fridkin SK. The changing face of fungal infections in health care settings. Clin Infect Dis 2005; 41: 1455–1460
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Benjamin DK, Jr, Kontoyiannis DP, et al. Infections due to Aspergillus terreus: a multicenter retrospective analysis of 83 cases. Clin Infect Dis 2004; 39: 192–198
   PubMed Web of Science ®Google Scholar
• Steinbach WJ, Perfect JR, Schell WA, Walsh TJ, Benjamin DK, Jr. In vitro analyses, animal models, and 60 clinical cases of invasive Aspergillus terreus infection. Antimicrob Agents Chemother 2004; 48: 3217–3225
   PubMed Web of Science ®Google Scholar
• Dannaoui E, Borel E, Persat F, Piens MA, Picot S. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis. J Med Microbiol 2000; 49: 601–606
   PubMed Web of Science ®Google Scholar
• Walsh TJ, Petraitis V, Petraitiene R, et al. Experimental pulmonary aspergillosis due to Aspergillus terreus: pathogenesis and treatment of an emerging fungal pathogen resistant to amphotericin B. J Infect Dis 2003; 188: 305–319
   PubMed Web of Science ®Google Scholar
• Warn PA, Morrissey G, Morrissey J, Denning DW. Activity of micafungin [FK463] against an itraconazole-resistant strain of Aspergillus fumigatus and a strain of Aspergillus terreus demonstrating in vivo resistance to amphotericin B. J Antimicrob Chemother 2003; 51: 913–919
   PubMed Web of Science ®Google Scholar
• Mosquera J, Warn PA, Morrissey J, et al. Susceptibility testing of Aspergillus flavus: inoculum dependence with itraconazole and lack of correlation between susceptibility to amphotericin B in vitro and outcome in vivo. Antimicrob Agents Chemother 2001; 45: 1456–1462
   PubMed Web of Science ®Google Scholar
• Johnson EM, Oakley KL, Radford SA, et al. Lack of correlation of in vitro amphotericin B susceptibility testing with outcome in a murine model of Aspergillus infection. J Antimicrob Chemother 2000; 45: 85–93
   PubMed Web of Science ®Google Scholar
• Denning DW, Stevens DA. Antifungal and surgical treatment of invasive aspergillosis: review of 2,121 published cases. Rev Infect Dis 1990; 12: 1147–1201
   PubMedGoogle Scholar
• Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37(Suppl. 3)S157–187
   PubMedGoogle Scholar
• Steinbach WJ, Stevens DA, Denning DW. Combination and sequential antifungal therapy for invasive aspergillosis: review of published in vitro and in vivo interactions and 6281 clinical cases from 1966 to 2001. Clin Infect Dis 2003; 37(Suppl. 3)S188–224
   Google Scholar
• Steinbach WJ, Stevens DA, Denning DW, Moss RB. Advances against aspergillosis. Clin Infect Dis 2003; 37(Suppl. 3)S155–156
   Google Scholar
• Clemons KV, Martinez M, Stevens DA. Efficacy of itraconazole alone and in combination with amphotericin B against pulmonary aspergillosis. In: 4th Congress of the European Confederation of Medical Mycology; 1998; Glasgow, Scotland; 1998: abst. 153.
   Google Scholar
• Schmitt HJ, Edwards F, Andrade J, Niki Y, Armstrong D. Comparison of azoles against aspergilli in vitro and in an experimental model of pulmonary aspergillosis. Chemother 1992; 38: 118–126
   PubMed Web of Science ®Google Scholar
• Lewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrob Agents Chemother 2002; 46: 3208–3214
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Coco BJ, Patterson TF. Sequential or combination antifungal therapy with voriconazole and liposomal amphotericin B in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2006; 50: 1567–1569
   PubMed Web of Science ®Google Scholar
• Dennis CG, Greco WR, Brun Y, et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006; 50: 422–427
   PubMed Web of Science ®Google Scholar
• Sivak O, Bartlett K, Risovic V, et al. Assessing the antifungal activity and toxicity profile of amphotericin B lipid complex (ABLC; Abelcet) in combination with caspofungin in experimental systemic aspergillosis. J Pharm Sci 2004; 93: 1382–1389
   PubMed Web of Science ®Google Scholar
• Kirkpatrick WR, Perea S, Coco BJ, Patterson TF. Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob Agents Chemother 2002; 46: 2564–2568
   PubMed Web of Science ®Google Scholar
• Petraitis V, Petraitiene R, Sarafandi AA, et al. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J Infect Dis 2003; 187: 1834–1843
   PubMed Web of Science ®Google Scholar
• Schmitt HJ, Bernard EM, Edwards FF, Armstrong D. Combination therapy in a model of pulmonary aspergillosis. Mycoses 1991; 34: 281–285
   PubMed Web of Science ®Google Scholar
• Sionov E, Mendlovic S, Segal E. Experimental systemic murine aspergillosis: treatment with polyene and caspofungin combination and G-CSF. J Antimicrob Chemother 2005; 56: 594–597
   PubMed Web of Science ®Google Scholar
• Kramer MR, Marshall SE, Denning DW, et al. Cyclosporine and itraconazole interaction in heart and lung transplant recipients. Ann Intern Med 1990; 113: 327–329
   PubMed Web of Science ®Google Scholar
• Tucker RM, Denning DW, Hanson LH, et al. Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations. Clin Infect Dis 1992; 14: 165–174
   PubMed Web of Science ®Google Scholar
• Blankenship JR, Steinbach WJ, Perfect JR, Heitman J. Teaching old drugs new tricks: reincarnating immunosuppressants as antifungal drugs. Curr Opin Investig Drugs 2003; 4: 192–199
   PubMedGoogle Scholar
• Nagai H, Guo J, Choi H, Kurup V. Interferon-gamma and tumor necrosis factor-alpha protect mice from invasive aspergillosis. J Infect Dis 1995; 172: 1554–1560
   PubMed Web of Science ®Google Scholar
• Rex JH, Bennett JE, Gallin JI, et al. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163: 849–852
   PubMed Web of Science ®Google Scholar
• Graybill JR, Bocanegra R, Najvar LK, Loebenberg D, Luther MF. Granulocyte colony-stimulating factor and azole antifungal therapy in murine aspergillosis: role of immune suppression. Antimicrob Agents Chemother 1998; 42: 2467–2473
   PubMed Web of Science ®Google Scholar
• Polak-Wyss A. Protective effect of human granulocyte colony-stimulating factor (hG-CSF) on Cryptococcus and Aspergillus infections in normal and immunosuppressed mice. Mycoses 1991; 34: 205–215
   PubMed Web of Science ®Google Scholar
• Uchida K, Yamamoto Y, Klein TW, Friedman H, Yamaguchi H. Granulocyte-colony stimulating factor facilitates the restoration of resistance to opportunistic fungi in leukopenic mice. J Med Vet Mycol 1992; 30: 293–300
   PubMedGoogle Scholar
• Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997; 16: 51–55
   PubMed Web of Science ®Google Scholar
• Kullberg BJ, van't Wout JW. Cytokines in the treatment of fungal infections. Biother 1994; 7: 195–210
   PubMedGoogle Scholar
• Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26: 1266–1269
   PubMed Web of Science ®Google Scholar
• Lutz JE, Stevens DA. Treatment of invasive aspergillosis. Intern Med 1995; 16: 25–31
   Google Scholar
• Chiller TM, Sobel RA, Luque JC, Clemons KV, Stevens DA. Efficacy of amphotericin B or itraconazole in a murine model of central nervous system Aspergillus infection. Antimicrob Agents Chemother 2003; 47: 813–815
   PubMed Web of Science ®Google Scholar
• Imai JK, Singh G, Clemons KV, Stevens DA. Efficacy of posaconazole in a murine model of central nervous system aspergillosis. Antimicrob Agents Chemother 2004; 48: 4063–4066
   PubMed Web of Science ®Google Scholar
• Lewis JS, Boucher HW, Lubowski TJ, et al. Cost advantage of voriconazole over amphotericin B deoxycholate for primary treatment of invasive aspergillosis. Pharmacother 2005; 25: 839–846
   PubMed Web of Science ®Google Scholar
• O'Day DM, Head WS, Robinson RD, Williams TE, Wolff R. Ocular pharmacokinetics of saperconazole in rabbits. A potential agent against keratomycoses. Arch Ophthalmol 1992; 110: 550–554
   PubMedGoogle Scholar
• Harrison JM, Glickman RD, Ballentine CS, et al. Retinal function assessed by ERG before and after induction of ocular aspergillosis and treatment by the anti-fungal, micafungin, in rabbits. Doc Ophthalmol 2005; 110: 37–55
   PubMed Web of Science ®Google Scholar
• Hogaboam CM, Carpenter KJ, Schuh JM, et al. The therapeutic potential in targeting CCR5 and CXCR4 receptors in infectious and allergic pulmonary disease. Pharmacol Ther 2005; 107: 314–328
   PubMed Web of Science ®Google Scholar
• Groll AH, Walsh TJ. Posaconazole: clinical pharmacology and potential for management of fungal infections. Expert Rev Anti Infect Ther 2005; 3: 467–487
   PubMedGoogle Scholar
• Andes D. Clinical pharmacodynamics of antifungals. Infect Dis Clin North Am 2003; 17: 635–649
   PubMed Web of Science ®Google Scholar
• Andes D. Pharmacokinetics and pharmacodynamics in the development of antifungal compounds. Curr Opin Investig Drugs 2003; 4: 991–998
   PubMedGoogle Scholar
• Andes D. Clinical utility of antifungal pharmacokinetics and pharmacodynamics. Curr Opin Infect Dis 2004; 17: 533–540
   PubMed Web of Science ®Google Scholar
• Wiederhold NP, Kontoyiannis DP, Chi J, et al. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity. J Infect Dis 2004; 190: 1464–1471
   PubMed Web of Science ®Google Scholar